## 4 Discussion  
The most important findings of the study were that the use of PRP in QTB ACLR may decrease the need for on-demand analgesia and accelerate ROM restoration as well as improve knee stability, lessen the extent of tibial tunnel widening and potentially diminish pain at 18 months postoperatively. A small elongation of the time of elevated body temperature and a small elevation in the mean body temperature were observed in the PRP group compared to the no-PRP \begin{table}
\begin{tabular}{c c c} \hline \hline
**Outcome** & **PRP Group, Mean** & **No-PRP Group, Mean** \\ \hline Time of presence of fever & 3.5 days & 3 days \\ \hline Body temperature & 37.7 \({}^{\circ}\)C & 37.4 \({}^{\circ}\)C \\ \hline Time of presence of palpable & 22 days & 21 days \\ hematoma/swelling & & \\ \hline Time of need for on-demand analgesia & 8 days & 11 days \\ Time to walking without crutches & 21 days & 25 days \\ \hline Time of restoring full knee extension & 40 days & 53 days \\ \hline Time of restoring 90\({}^{\circ}\) of knee flexion & 21 days & 25 days \\ \hline _PRP, platelet-rich protein; \({}^{\circ}\)C, Cdissus degrees._ & \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Early postoperative outcomes. \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Outcome** & **PRP Group** & **No-PRP Group** & \(p\)**Value Availability** \\ \hline Harvest site pain, number of patients & 3/54 patients & 3/52 patients & NA \\ \hline Harvest site pain, intensity scale 0–3 & mean 1.3 & mean 2.3 & NA \\ \hline Dynamic test score scale 0–2 & mean 1.98 & mean 1.8 & NA \\ \hline KOOS Symptoms & mean 92 & mean 90 & NA \\ \hline KOOS Pain & mean 93 & mean 89 & NA \\ \hline KOOS Function daily living & mean 94 & mean 92 & NA \\ \hline KOOS Function sport activities & mean 90 & mean 88 & NA \\ \hline KOOS Quality of live & mean 83 & mean 85 & NA \\ \hline IKDC grade A & 17 patients & 16 patients & A \\ \hline IKDC grade B & 36 patients & 32 patients & A \\ \hline IKDC grade C & 1 patients & 2 patients & A \\ \hline IKDC grade D & 0 patients & 2 patients & A \\ \hline Anterior tibial translation SSD & 1.3 mm & 2.7 mm & NA \\ \hline Presence of tibial widening & 23/54 patients & 28/52 patients & A \\ \hline Mean tibial widening & 1.4 mm & 2.1 mm & NA \\ \hline \hline \end{tabular}
\begin{tabular}{c} _PRP, platelet-rich plasma; KOOS, Knee injury and Osteoarthritis Outcome Score; IKDC, International Knee Documentation Committee; SSD, side to_ \\ _side difference; NA, not available; A, available._ \\ \end{tabular}
\end{table} 
Table 2: Functional outcomes at 18 months postoperatively. group. Mean body temperature did not exceed 38 Celsius degrees, in agreement with the study of [PERSON] et al., who reported no case of fever in the series of 30 patients who underwent PRP injection in the knee [15]. Regarding the presence of hematoma/swelling, there was only a slight difference in time of their presence between groups in our study. Such data supports the results of [PERSON] et al., who reported no significant difference in postoperative swelling between PRP and control groups [16]. Patients in the PRP group needed on-demand analgesia for an average 3 days less than patients in the no-PRP group. This corresponds with the results of [PERSON] et al., who reported a lower Visual Analog Score (VAS) in the PRP group on the first postoperative day [17]. Patients who had PRP administration were able to walk without crutches for an average of 4 days faster than patients from the no-PRP group. To our knowledge, no data regarding the impact of PRP on the necessity of crutches support were reported in the literature. What is more, both restoration of full knee extension and 90 degrees knee flexion occurred earlier in the PRP group. This stands in contrast to the study of [PERSON] et al., who showed no significant difference in the range of knee motion when adding PRP to the ACLR [18]. Such outcomes of our study could result from earlier walking without crutches.